Plain-English translation of NCT06923111 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Sickle Cell Disease research guide →This trial is studying , a liquid form of hydroxycarbamide, to see how safe it is and how well it works at preventing painful and dangerous complications in very young children with sickle cell disease. Researchers will follow children who start taking this medication and compare their health outcomes over 2 years to similar children who did not receive the medication, using information from their regular medical visits and health records.
Sickle cell disease causes serious complications in young children, and doctors want to prevent these problems early in life. This medication has shown promise, but there is limited safety and effectiveness data specifically in babies and toddlers under 2 years old, so this study will gather real-world information to understand how the treatment works in this very young age group.
You likely qualify if…
You likely don't qualify if…
If your child is starting this medication, your doctor will enroll them in the study, and researchers will gather information from your regular clinic visits and health records over the next 2 years—no extra study visits or procedures are required, as everything comes from standard medical care. The study team will track how your child is doing, what side effects occur (if any), and how well the medication is preventing sickle cell complications, whether your child continues the medication, stops it, or switches to a different form.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
Germany
United Kingdom